Summary
The pharmacokinetics of vinorelbine has been investigated by a new HPLC method in 8 cancer patients receiving 8 weekly doses (30 mg·m−2) administered by brief infusion (15 min).
The plasma concentration-time curves showed a tri-exponential decay with a long terminal half-life (44.7 h) and a high volume of distribution (Vz=75.61·kg−1). The concentrations after the 8th infusion were significantly lower than after the 1st infusion, but without significant modification of CL (1.28 l·h−1·kg−1) or AUC (0.80 mg·l−1·h).
The pharmacokinetic parameters exhibited wide inter-individual variations. The results are consistent with those of previous RIA studies, although the HPLC method appears to be more specific and more precise.
Similar content being viewed by others
References
Mangeney P, Andriamialisoa RZ, Lallemand JY, Langlois N, Langlois Y, Potier P (1979) 5'-noranhydrovinblastine. Prototype of a new class of vinblastine derivatives. Tetrahedron 35: 2175–2179
Mangeney P, Andriamialisoa RZ, Lallemand JY, Langlois N, Langlois Y, Potier P (1979) A new class of antitumor compounds: 5'-nor and 5',6'-seco derivatives of vinblastine-type alkaloids. J Org Chem 44: 3765–3768
Rahmani R, Martin M, Barbet J, Cano JP (1984) Radioimmunoassay and preliminary pharmacokinetic studies in rats of 5'-noranhydrovinblastine (Navelbine). Cancer Res 44: 5609–5613
Ribaud P, Gouveia J, Maral R, Potier P, Jasmin C, Mathé G (1981) Phase I study of noranhydrovinblastine (Navelbine, NVB). Abstract publication. Proc Am Assoc Cancer Res 22: 368
Favre R, Garnier G, Depierre A, Samak R, Cano JP, Carcassonne Y (1985) A phase I study of Navelbine(nor-5' anhydrovinblastine). In: Ishigami J (ed) 14th International Congress of Chemotherapy. International Society of Chemotherapy. University of Tokyo Press. Tokyo, Japan, pp 343
Rahmani R, Guéritte F, Martin M, Just S, Cano JP, Barbet J (1986) Comparative pharmacokinetics of antitumor vinca alkaloids: intravenous bolus injections of Navelbine and related alkaloids to cancer patients and rats. Cancer Chemother Pharmacol 16: 223–228
Rahmani R, Bruno R, Iliadis A, Favre R, Just S, Barbet J, Cano JP (1987) Clinical pharmacokinetics of the antitumor drug Navelbine (5'-noranhydrovinblastine). Cancer Res 47: 5796–5799
Krikorian A, Rahmani M, Bromet M, Boré P, Cano JP (1989) Pharmacokinetics and metabolism of navelbine. Semin Oncol 16 [Suppl 4]: 21–25
Nicot G, Lachatre G, Marquet P, Bonnaud F, Valette JP, Rocca JL (1990) High performance liquid chromatographic determination of Navelbine in human plasma and urine. J Chromatogr 528: 258–266
Aronson JK, Dengler HJ, Dettli L, Follath F (1988) Standardization of symbols in clinical pharmacology. Eur J Clin Pharmacol 35: 1–7
Boré P, Rahmani R, Van Cantfort J, Focan C, Cano JP (1989) Pharmacokinetics of a new anticancer drug, Navelbine, in patients. Cancer Chemother Pharmacol 23: 247–251
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Marquet, P., Lachatre, G., Debord, J. et al. Pharmacokinetics of vinorelbine in man. Eur J Clin Pharmacol 42, 545–547 (1992). https://doi.org/10.1007/BF00314866
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00314866